Avanos Medical

Avanos Medical is a publicly traded medical device company with a dual focus on Pain Management & Recovery and Enteral Feeding. A key strategic achievement is the inclusion of its ON-Q and ambIT infusion pumps under the new CMS reimbursement rules from the NOPAIN Act, effective January 2025, which validates its non-opioid approach and creates a significant market catalyst. The company's strategy leverages its established global commercial footprint, a portfolio of trusted brands, and targeted innovation to address the opioid crisis and the critical need for reliable nutritional support across care settings.

Avanos leverages a diversified portfolio of medical device platforms including local infusion pump systems (elastomeric and electronic), radiofrequency ablation (cooled, tined, conventional), electromagnetic enteral tube guidance, and specialized neonatal feeding systems.

Avanos competes in fragmented markets against giants like BD, Boston Scientific, Abbott, and Cardinal Health. Its strategy is not cost-based but relies on clinical differentiation, strong brand equity (ON-Q, MIC-KEY, COOLIEF), and a unique reimbursement advantage for its pain pumps following the NOPAIN Act.